Blood proteins that shift during menopause track a 15% higher Alzheimer's risk in older women

The 15% figure comes from women measured late in life. The women in the risk analysis were in their 60s and 70s, and their data came from the archives of four longitudinal cohorts ^[6]. The midlife measurements came from a separate group of 80 women in their 40s and 50s ^[2]. The molecules connect the two groups: the 16 proteins that shift across menopausal stages are the ones found elevated in the older women at higher risk ^[1][6].

The midlife half is the most careful part of the design. The team staged each woman with the STRAW+10 criteria and tested the proteins against estradiol and follicle-stimulating hormone ^[3]. That ties the shifts to the hormonal transition and not to chronological age alone ^[3]. Sixteen of the more than 100 proteins on the panel moved together across stages ^[1][2]. Eighty women is a small sample for screening a panel that size. The UK Biobank replication, with about 35 times as many women as the discovery group, is the check against a chance result ^[5][11].

A 15% increase is a relative figure. The release does not give the baseline risk, the comparison group or a confidence interval, so the figure cannot be turned into extra cases per thousand women ^[6].

The night-sweats result is weaker in its late-life half. In the older cohorts, the inflammatory signature was matched to symptoms women remembered from decades earlier ^[7]. The data link symptoms and inflammation without showing which comes first.

The case for looking at midlife rests on timing. According to the release, Alzheimer's pathology starts building decades before memory problems appear ^[12]. Two-thirds of diagnoses are in women, and researchers have struggled to explain that gap through longer lifespans alone ^[8]. Kaitlin Casaletto, an associate professor at the UCSF Fein Memory and Aging Center and co-senior author of the study, was careful about causation. "We don't think that menopause is directly causing dementia," she said ^[9]. "But it's possible that we may be able to predict a woman's risk for dementia decades later by the levels of these molecules around menopause." ^[10]

I think the evidence supports the 16 proteins as a candidate panel to test at menopause. As the release describes the study, the midlife and late-life measurements come from different women ^[2][6]. To show that a blood draw during the transition predicts one woman's dementia risk, researchers would need samples taken at menopause and follow-up through to diagnosis.